pembrolizumab,lenvatinib
merck,eisai
['leap-002', 'lenva', 'pembro']
the full dataset from leap-002 comparing #lenvatinib #pembrolizumab vs. #lenvatinib placebo was presented today highlights are median os 21.2 mos for combo vs. 19 mos for lenvatinib alone not meeting statistical significance. my thoughts follow #livertwitter
Prof. Medicine, @cwrusom /Medical Dir &distinguished physician, Liver Center, @UHhospitals /Lead, Multidisciplinary Hepatobiliary Tumor Team, Seidman Cancer Ctr